Skip to main content
SpringerLink
Log in

Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Domperidone is a useful alternative to metoclopramide for treatment of gastroparesis due to better tolerability. Effectiveness and side-effects from domperidone may be influenced by patient-related factors including polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, and domperidone targets.

Aims

The aim of this study was to determine if demographic and pharmacogenetic parameters of patients receiving domperidone are associated with response to treatment or side-effects.

Methods

Patients treated with domperidone for gastroparesis provided saliva samples from which DNA was extracted. Fourteen single-nucleotide polymorphisms (SNPs) in seven candidate genes (ABCB1, CYP2D6, DRD2, KCNE1, KCNE2, KCNH2, KCNQ1) were used for genotyping. SNP microarrays were used to assess single-nucleotide polymorphisms in the ADRA1A, ADRA1B, and ADRA1D loci.

Results

Forty-eight patients treated with domperidone participated in the study. DNA was successfully obtained from each patient. Age was associated with effectiveness of domperidone (p = 0.0088). Genetic polymorphism in KCNH2 was associated with effectiveness of domperidone (p = 0.041). The efficacious dose was associated with polymorphism in ABCB1 gene (p = 0.0277). The side-effects of domperidone were significantly associated with the SNPs in the promoter region of ADRA1D gene.

Conclusions

Genetic characteristics associated with response to domperidone therapy included polymorphisms in the drug transporter gene ABCB1, the potassium channel KCNH2 gene, and α1D—adrenoceptor ADRA1D gene. Age was associated with a beneficial response to domperidone. If verified in a larger population, this information might be used to help determine which patients with gastroparesis might respond to domperidone and avoid treatment in those who might develop side-effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Parkman HP, Hasler WL, Fisher RS. American gastroenterological association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1592–1622.

    Article  PubMed  Google Scholar 

  2. Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med. 2007;356:820–829.

    Article  CAS  PubMed  Google Scholar 

  3. Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil. 2006;18:263–283.

    Article  CAS  PubMed  Google Scholar 

  4. Ahmad N, Keith-Ferris J, Gooden E, Abell T. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol. 2006;6:571–576.

    Article  CAS  PubMed  Google Scholar 

  5. Franzese A, Borrelli O, Corrado G, et al. Domperidone is more effective than cisapride in children with diabetic gastroparesis. Aliment Pharmacol Ther. 2002;16:951–957.

    Article  CAS  PubMed  Google Scholar 

  6. Dumitrascu DL, Weinbeck M. Domperidone versus metoclopramide in the treatment of diabetic gastroparesis. Am J Gastroenterol. 2000;95:316–317.

    Article  CAS  PubMed  Google Scholar 

  7. Sadee W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet. 2005;14 Spec No. 2:R207–R214.

    Google Scholar 

  8. Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Desta Z. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004;58:277–287.

    Article  CAS  PubMed  Google Scholar 

  9. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull. 2002;25:1391–1400.

    Article  CAS  PubMed  Google Scholar 

  10. Schinkel AH. The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv Exp Med Biol. 2001;500:365–372.

    CAS  PubMed  Google Scholar 

  11. Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26:720–723.

    Article  CAS  PubMed  Google Scholar 

  12. Pfeufer A, Jalilzadeh S, Perz S, et al. Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circ Res. 2005;96:693–701.

    Article  CAS  PubMed  Google Scholar 

  13. Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol. 2000;95:1456–1462.

    Article  CAS  PubMed  Google Scholar 

  14. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy. A joint report of the Society of Nuclear Medicine and the American Neurogastroenterology and Motility Society. Am J Gastroenterol. 2008;103:753–763.

    Article  PubMed  Google Scholar 

  15. Maranki JL, Lytes V, Meilahn JE, et al. Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis. Dig Dis Sci. 2008;53(8):2072–2078.

    Article  PubMed  Google Scholar 

  16. Krynetskiy E, McDonald O, Dervieux T, Evans W. Molecular diagnostics of thiopurine S-methyltransferase deficiency in cancer drug therapy. In: Wong SHY, Linder MW, Valdes R, eds. Pharmacogenomics and proteomics. Washington, DC: AACC Press; 2006:251–258.

    Google Scholar 

  17. Liu K, Muse SV. PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics. 2005;21:2128–2129.

    Article  CAS  PubMed  Google Scholar 

  18. Uchida H, Mamo DC. Dosing of antipsychotics in schizophrenia across the life-spectrum. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(6):917–920.

    Article  CAS  PubMed  Google Scholar 

  19. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA. 1994;91(8):3438–3442.

    Article  CAS  PubMed  Google Scholar 

  20. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc. 2003;78(12):1479–1487.

    Article  CAS  PubMed  Google Scholar 

  21. Sun Z, Milos PM, Thompson JF, et al. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced torsades de pointes. J Mol Cell Cardiol. 2004;37(5):1031–1039.

    Article  CAS  PubMed  Google Scholar 

  22. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58(1):32–45.

    Article  CAS  PubMed  Google Scholar 

  23. Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26(5):720–723.

    Article  CAS  PubMed  Google Scholar 

  24. Stork D, Timin EN, Berjukow S, et al. State dependent dissociation of HERG channel inhibitors. Br J Pharmacol. 2007;151(8):1368–1376.

    Article  CAS  PubMed  Google Scholar 

  25. Djeddi D, Kongolo G, Lefaix C, Mounard J, Leke A. Effect of domperidone on QT interval in neonates. J Pediatr. 2008;153(5):663–666.

    Article  CAS  PubMed  Google Scholar 

  26. Gouas L, Nicaud V, Chaouch S, et al. Confirmation of associations between ion channel gene SNPs and QTc interval duration in healthy subjects. Eur J Hum Genet. 2007;15:974–979.

    Article  CAS  PubMed  Google Scholar 

  27. Ward BA, Morocho A, Kandi A, Galinsky RE, Flockhart DA, Desta Z. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004;58:277–287.

    Article  CAS  PubMed  Google Scholar 

  28. Simard C, Michaud V, Gibbs B, et al. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica. 2004;34:1013–1023.

    Article  CAS  PubMed  Google Scholar 

  29. Perera MA. The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert Opin Drug Metab Toxicol. 2010;6:17–28.

    Article  CAS  PubMed  Google Scholar 

  30. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta. 2009;1794:860–871.

    CAS  PubMed  Google Scholar 

  31. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003;46(9):1716–1725.

    Article  CAS  PubMed  Google Scholar 

  32. Gow JM, Hodges LM, Chinn LW, Kroetz DL. Substrate-dependent effects of human ABCB1 coding polymorphisms. J Pharmacol Exp Ther. 2008;325:435–442.

    Article  CAS  PubMed  Google Scholar 

  33. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol. 2002;62:1–6.

    Article  CAS  PubMed  Google Scholar 

  34. McBride BF, Yang T, Roden DM. Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics J. 2009;9:194–201.

    Article  CAS  PubMed  Google Scholar 

  35. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462(7270):175–181.

    Article  CAS  PubMed  Google Scholar 

  36. Clark DA, Arranz MJ, Mata I, Lopez-Ilundain J, Perez-Nievas F, Kerwin RW. Polymorphisms in the promoter region of the alpha1A-adrenoceptor gene are associated with schizophrenia/schizoaffective disorder in a Spanish isolate population. Biol Psychiatry. 2005;58(6):435–439.

    Article  CAS  PubMed  Google Scholar 

  37. Nonen S, Okamoto H, Fujio Y, et al. Polymorphisms of norepinephrine transporter and adrenergic receptor alpha1D are associated with the response to beta-blockers in dilated cardiomyopathy. Pharmacogenomics J. 2008;8(1):78–84.

    Article  CAS  PubMed  Google Scholar 

  38. Ma J, Rayner CK, Jones KL, Horowitz M. Diabetic gastroparesis: diagnosis and management. Drugs. 2009;69:971–986.

    Article  CAS  PubMed  Google Scholar 

  39. Lacy BE, Weiser K. Gastrointestinal motility disorders: an update. Dig Dis. 2006;24:228–242.

    Article  PubMed  Google Scholar 

  40. Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 study group. Clin Ther. 1998;20:438–453.

    Article  CAS  PubMed  Google Scholar 

  41. Sawant P, Das HS, Desai N, et al. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia. J Assoc Physicians India. 2004;52:626–628.

    PubMed  Google Scholar 

  42. Hegar B, Alatas S, Advani N, et al. Domperidone versus cisapride in the treatment of infant regurgitation and increased acid gastro-oesophageal reflux: a pilot study. Acta Paediatr. 2009;98:750–755.

    Article  CAS  PubMed  Google Scholar 

  43. Gunlemez A, Babaoglu A, Arisoy AE, et al. Effect of domperidone on the QTc interval in premature infants. J Perinatol. 2010;30:50–53.

    Article  CAS  PubMed  Google Scholar 

  44. Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26:720–723.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by Seed Grant from Temple University (to HP, MJ, and EK), and by Jayne Haines Center for Pharmacogenomics and Drug Safety, Temple University School of Pharmacy.

Author information

Authors and Affiliations

  1. Gastroenterology Section, School of Medicine, Temple University School of Medicine, Parkinson Pavilion, 8th floor, 3401 North Broad Street, Philadelphia, PA, 19140, USA

    Henry P. Parkman & Priyanka Sachdeva

  2. Temple University School of Pharmacy, Philadelphia, PA, USA

    Michael R. Jacobs, Anurag Mishra, Jessica A. Hurdle & Evgeny Krynetskiy

  3. Biostatistics Consulting Center, Temple University School of Medicine, Philadelphia, PA, USA

    John P. Gaughan

Authors
  1. Henry P. Parkman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael R. Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anurag Mishra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jessica A. Hurdle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Priyanka Sachdeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John P. Gaughan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Evgeny Krynetskiy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henry P. Parkman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parkman, H.P., Jacobs, M.R., Mishra, A. et al. Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects. Dig Dis Sci 56, 115–124 (2011). https://doi.org/10.1007/s10620-010-1472-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-010-1472-2

Keywords

Search

Navigation